Why Mainstream Lyme/MSIDS Research Remains in the Dark Ages

By Alicia Cashman

Recently, a study came out by Wormser et al. on the efficacy of a 14-day course of amoxicillin for patients with erythema migrans (EM).  The study purports to be the first clinical study in the U.S. that validates this regimen but states foreign studies have already done so (1).

The most glaring issue with this study is the continuing fixation on the acute stage while continuing to completely ignore treated patients who remain ill.  I refuse to say the words “late stage” as experience has shown “late stage” can happen within two weeks after tick bite.  Bob Giguere of IGeneX told our support group the story of a little girl who developed facial palsy and lost the ability to walk & talk within 4-6 hours of tick bite (2).  Whether or not you label that escalating case “late stage” or not, the infection was able to cross the blood brain barrier and cause severe symptoms in short order.

There were other numerous problems with the study:

  • The small sample size of only 24 patients.
  • The continued use of the “bull’s-eye” rash when only 27-80% get it depending on who’s counting, leaving out a large subset of patients (3). An inconvenient truth is that only a quarter of the first ever patient sample had a rash: 1976circularletterpdf
  • Regarding EM rashes, the study ignores evidence assessments and guideline recommendations that state clearance of the rash does not mean infection clearance (4).
  • The continued denial of the pleomorphic (shape-shifting) & polymicrobial (multiple pathogens) nature of this illness (5).  Pleomorphism allows the organism to hide and reemerge later.  Coinfection involvement makes cases more severe.  Both issues should be factored into any treatment plan.  MSIDS means multi systemic infectious disease syndrome – a far better moniker as it’s often much more than Lyme (borrelia) at play.
  • The lack of lengthy follow-up required due to the plethora of recorded treatment failures in the literature as well as the complete denial of the recommendation to continually treat patients who have not fully recovered until symptom resolution (2).

Microbiologist Tom Grier has written on the issue of treatment failure for years and states that from the very beginning, treatment failures were seen in nearly every antibiotic study done.  He also states that the longer the patient follow up, the higher the treatment failure (6).  

You would think the totality of these facts would set researchers on a different course yet researchers such as Dr. Gary Wormser seem hell-bent on conducting yet more research with a severely limited patient group, short term treatment and follow up, pushing the EM rash criteria, and ignoring those with persistent symptoms.

MSIDS patient and advocate Carl Tuttle has been working tirelessly to let researchers, the IDSA, the tick-borne disease working group, and politicians know these significant facts by refuting the continuing skewed & faulty research.  He writes these entities personally, and has also started the online petition Calling for a Congressional Investigation of the CDC, IDSA, and ALDF:  https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf  If you’ve always wondered what you can do to affect change, add your name to the over 70,000 people who are refusing to accept the current standard of research and care.  Then, if you have the energy, write these folks yourself.  Tuttle includes all the pertinent information for you to cut and paste the material that will let your voice be heard.

Circling back to the practical and important issue of treatment failure faced by many patients, it’s important to rewind time, and learn the sordid and politically motivated history of the treatment of Lyme.

Dr. Burrascano, a prominent and experienced doctor who treated Lyme for decades, recently made a must-see video for patient and doctor alike.  Within this short 40 minute video he outlines chronological events that explain the mishandling of this disease as well as the years of treatment trial and error within his own practice utilizing microscopy, a far better method of Borrelia detection.  He debunks much of what is blindly accepted in main-stream medicine, including the extremely biased and faulty science in Wormser’s study.  

Highlights of the video (7):

  • Dr. Burrascano’s office was 10 minutes from Shelter Island where Willy Burgdorfer collected ticks. Patients with mysterious symptoms graced his practice from inception.

 

  • Early Lyme was described in Europe even as far back as the 1800s as causing dermatological, neurological, rheumatological, & neuropsychiatric problems.  He claims that early history was lost.

 

  • In the U.S., as far back as 1965, a condition known as ‘Montauk Knee’ was described as well as a circular rash that would clear up more quickly with penicillin.  In 1970 the first paper was published about a physician who was infected while grouse hunting in our very own state of Wisconsin.  Thankfully, the patient presented with EM rash and Dr. Rudolf J. Scrimenti, a Minnesotan dermatologist who was familiar with the European literature, effectively used penicillin during the acute phase of the illness (8).

 

  • Polly Murray of Connecticut contacted the CDC about an abnormal amount of sick kids with rashes and joint pain in the early ’70s and the CDC sent epidemiologist and rheumatologist Dr. Allen Steere to determine the cause.  Scrimenti wrote Steere and even went to Yale to warn him of the European studies and that Lyme clusters could exist in the U.S. Despite the warnings, Steere concluded what was occurring in Lyme, Connecticut was nothing more than an unrecognized form of juvenile arthritis (8). Later, Willy Burgdorfer found the cause to be Borrelia burgdorferi (Bb), commonly known as Lyme disease.

 

  • As early as 1985, Pathologist Dr. Alan McDonald developed a culturing technique that showed spirochetes in the blood.  He proved patients can test negative yet still have active infection as shown in blood culture.  Seronegativity for some reason remains controversial to this day.

 

  • Some patients under Dr. Steere’s treatment in the 80’s got better but many didn’t, so he arbitrarily divided patients into two groups: Major symptoms: Cardiac, arthritic, Bells palsy and Minor symptoms: everything else.  He claimed that successful treatment was the clearing of major symptoms, but 95% of patients with major symptoms found symptoms to clear on their own without any treatment, demonstrating his treatment theory was completely bogus. All those with “minor” symptoms he labeled post Lyme syndrome – a label which has persisted to this day, but there has never been a description explaining what this syndrome is from an immunological standpoint that applies to patients.

Microbiologist Holly Ahern recently wrote about the arbitrary label “Post Treatment Lyme Disease Syndrome,” or PTLDS, which the CDC estimates to be 10-20% of patients; however, Ahern states this label only truly represents a subgroup of patients who have been diagnosed early, treated with standard short-term antibiotics, and whom remained symptomatic or developed new symptoms. It does not and should not include a third group who were misdiagnosed or undiagnosed beyond the first few weeks of infection. She states estimates based on existing research show this unaccounted for group makes up 30-40% of Lyme disease patients. By combining the PTLDS group with the third group, there are 60% of patients ending up with chronic symptoms, a number that more closely matches my experience as a patient advocate (9).

This is an important point as researchers continue to downplay the aspect of persistent symptoms by using the falsely skewed low percentages.
  • Burrascao worked with dermatologist Dr. Bernard Berger and Pathologist, Dr. Alan McDonald, and they cultured EM biopsies for antibiotic sensitivity studies.  Decades ago they knew amoxicillin worked better than penicillin, doxycycline worked better than tetracycline, and while erythromycin worked in a test tube, it didn’t work well in patients.  Burrascano never ascribed to Steere’s pre and post Lyme categories but rather would treat and then wait a few weeks to culture. All the cultures came back positive.  He learned even way back in the 80’s that these patients had continuing persistent Lyme infection. 

 

  • He also manipulated drug levels. While some patients in- Burrascano’s in house studies had detectable levels, others required higher doses to achieve the same level.  If you don’t have detectable blood levels of antibiotics, you will not be killing pathogens. The CDC guidelines, be it the 200 mg of daily doxycycline or the 500 mg of amoxicillin given in the Wormser study, are both faulty in that they are a one size approach negating entirely the issue of effective drug blood levels. Burrascano is concerned the CDC is setting patients up for severe chronic Lyme because if pathogens aren’t killed they are left to mutate into something that will become treatment resistant.   

 

  • While the recent Wormser et al. study used 500 mg of amoxycillin three times a day, Burrascano, decades ago, found patients had more improvement on 1000mg three times a day. When he added 500 mg probenecid three times a day, which increases antibiotic blood levels, they improved even more.  Regarding dosages, he explained about an unpublished study with Stoneybrook where there was a failure rate of 100% of patients taking 300 mg of doxycycline a day for 21 days. Yet, how many people are given this exact treatment today?  He found patients required 400 mg as a starting point with many needing 600 mg.

 

  • Armed with this intel, he then did clinical studies manipulating treatment time with amoxycillin and probenecid. Due to the varying clinical outcomes he defined treatment success as getting back to pre-illness state for 3 months without relapse.  He found 14 days didn’t do much, with 17% doing well after 1 month, and 66% of males plateauing at 4 months, but hormonally active women not until 6 months. 

 

  • Regarding cefuroxime, he found that 3 weeks after treatment, patients were still culture positive and complaining of symptoms after 14 days of high doses – a 100% failure rate.  Eventually he discovered that Ceftin did work on patients who failed amoxycillin if the dose was high enough for long enough.

 

  • Because patients weren’t getting better, he took a week off work, and sat down with his coworkers who created spreadsheets of all his patients.  He found the following variables necessitated longer treatment:
  1. Multiple bites
  2. Active Lyme arthritis with a high sedimentation rate
  3. Heart murmurs
  4. Hormonally active women

He found IV’s give much higher blood levels of drugs than orals, and that the following variables necessitated IV treatment:

  1. Spinal tap shows high inflammation (high protein)
  2. High Sed rate and synovitis (inflammation of synovial membrane)
  3. People sick for more than 1 year
  4. Age over 60
  5. Acute carditis
  6. Immune deficiency
  7. Those who used immunosuppressants
  8. Failed oral treatment

To further demonstrate the polarization of how Lyme is treated, a recent report was published by the U.S. Centers for Disease Control and Prevention with the aim of frightening doctors from using IV therapy at all.  The article published in MMWR, was of five extreme cases with poor outcomes amid thousands who have been treated successfully. Two of the ten authors work for the CDC and are personally involved in updating Lyme guidelines for the IDSA, a group that doesn’t even believe in chronic Lyme.  Furthermore, one of the authors solicited IDSA doctors for evidence of harm while dangling the promise of co-authorship of the report, while not soliciting for any success stories using IV therapy (10).  This sort of partiality is rife in Lyme/MSIDS research.

On the other hand, an IDSA founder from our very own state of Wisconsin wrote a book on 51 cases of chronic Lyme where he often used 6-8 grams of IV antibiotics daily with success.

He first learned of the debilitating nature of Lyme in the late 80’s after a son of a woman dying from ALS suggested his mother’s illness may have started when she developed a severe case of Lyme Disease.  He wrote that many of his colleagues denied chronic Lyme (11).

  • Burrascano found Lyme disease has a 4-week cycle, where every 4 weeks patients experience a symptom flair. Burgdorfer found this in mice studies, and IGeneX found the same thing in urine antigen studies.  Borrelia grow and are active, then become inactive.  Four weeks later they activate.  This has been shown recently in vitro. Think of Bb as a slow relapsing fever.  This nuance is important because antibiotics only kill during the active phase.  You need a minimum of a month to bracket a whole generation cycle.  

 

  • When patients reach a plateau, he recommends cycling therapy where you discontinue antibiotics until symptoms return.  Then, return to full treatment until symptoms are gone. He states that many patients become symptom free after 4 of these cycles.  He used this on himself with success.

 

  • Burrascano found 3 other physicians doing the exact same thing with patients. This approached worked for all of them despite the different geographical areas they were in.

 

  • The government came up with a gold stain for detecting Bb, and found Bb excreted bioproducts and an S layer (slime to create a biofilm) even in the dormant phase. Their work even then showed infected animals had gold stained spirochetes in the following areas: bladder, brain, blood, heart, liver, spleen, urine, tears, and in ticks.

 

  • The government, in conjunction with Burrascano, conducted studies on 73 chronically ill Lyme patients.  Bb was found in 48 of 50 samples of tears, showing that 53% still had living Borrelia antigens that could be seen on the gold stain. 

 

  • They also found if you tested patients who still had symptoms, and then took a couple weeks break for treatment, 100% still were positive for Lyme (living organisms) by gold stain.  The NIH abruptly stopped funding of gold stain, made them close the whole thing down, and never asked front-line Lyme docs for specimens again.

 

  • Burrascano states that in those early days they didn’t know anything about coinfections but patients did well on the Lyme-only treatment at that time; however, the patients that did show involvement were the ones who appeared chronically infected. He found if patients were treated early and hard for Lyme the coinfections weren’t a problem for most.

 

  • Burrascano then discusses the importance of proper exercise for Lyme patients, and that without exercise, patients don’t recover.  The goal of exercise is to increase T-cells, so exercise cannot be too strenuous or too often.  He recommends light exercise making sure to give enough time in between sessions for the body to recover.  It is also important to get good sleep, and to rest as needed.

 

  • He gave the story of how Dr. McDonald presented his culture findings (direct testing) at a meeting of the NY State medical society where there were many detractors from Yale & Stoneybrook who didn’t want their patented serological tests to be usurped. They accused him of falsifying his results.  Dr. McDonald then went on to prove conclusively it was Lyme by morphology, silver staining, monoclonal antibodies staining, DNA PCR and finally electron microscopy.  Frustrated, he quit the field and moved to Texas leaving all his old files in Burrascano’s basement until twenty years went by and he became interested again due to Alzheimer’s research & picked up his old files. 

There has been an ongoing record of suppression of microscopy for Lyme.  In an interview with now retired professor of microbiology Morten Laane, the facts come rolling out on how he was fired, his lab was closed down, and his published article disappeared without a trace after presenting his findings at a scientific conference on how microscopy showed spirochetes as well as other organisms like Babesia in a number of patients (12).  Laane is far from alone.  Dr. Sin Hang Lee has even filed a $57.1 million lawsuit against the CDC for suppressing direct detection tests, and for employing ‘Lysenkoism,’ a term used for a Russian political campaign using bogus science to suppress true biological and medical sciences and to punish scientists and doctors who don’t follow Party Line (13).

  • Burrascano connected McDonald with Dr. Eva Sapi to develop a culture technique based on McDonald’s 1985 test.  Advanced Lab contracted with Sapi to develop a commercial test using human specimens instead of lab specimens, and they went on to perform over 8,000 successful cultures of which published studies showed the test was 92% sensitive, and 100% specific.  Advanced labs closed but sold the test to IGeneX & it is currently in the process of getting approval.

Dr. Burrascano’s timely and detailed video reveals clearly why many remain ill.  There are stake holders who are purposely using their power to deny thousands if not millions proper diagnosis and treatment for a disease that is over 40 years old.  There are nuances to treating Lyme that researchers and therefore doctors are still not taking into account, which means doctors are utilizing flawed and biased studies from the Dark Ages in treating patients.  Extremely ill patients are left to suffer.

Most researchers continue to fixate on the acute phase, ignore published animals studies, international studies, the advice and experience of  Lyme doctors trained by ILADS, and purposely suppress much better testing.

It is imperative that we continue to educate ourselves and others, so we do not fall prey to ancient perceptions of a disease that has become a pandemic and shows no signs of slowing down.

Medicine fails when it quits listening. 

References:  

 1.  Wormser GP, Brady KC, Cho, MS, Scavarda CA, McKenna D.  (2019) Efficacy of a 14-day course of amoxicillin for patients with erythema migraines.  Diagnostic Microbiology and Infectious Disease.  https://doi.org/10.1016/j.diagmicrobio.2019.01.003

2.   IGeneX presentation to the Madison Lyme Support Group.  https://madisonarealymesupportgroup.com/2016/12/07/igenex-presentation/

3.  Johnson, Lorraine.  “How Many of Those With Lyme disease Have the Rash?  Estimates range from 27-80%.” lymedisease.org, 10 April 2014, https://www.lymedisease.org/lymepolicywonk-how-many-of-those-with-lyme-disease-have-the-rash-estimates-range-from-27-80-2/.  Accessed 12 February, 2019.

4.  Cameron, DJ, Johnson LB, Maloney, EL.  (2014)  Evidence Assessments and Guideline Recommendations in Lyme disease:  the Clinical Management of Known Tick Bites, Erythema Migrans Rashes and Persistent Disease.  Expert Review of Anti-infective Therapy.  https://doi.org/10.1586/14787210.2014.940900

5.  Garg K, Merilainen L, Franz O, Pirttinen H, Quevedo-Diaz M, Croucher S, Gilbert L. (2018) Evaluating Polymicrobial Immune Responses in Patients Suffering From Tick-borne Diseases.  Scientific Reports.  doi: 10.1038/s41598-018-34393-9  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206025/

6.  Grier, Tom.  “Chronic Lyme Post-mortem Study Needed.”  madisonarealymesupportgroup.com, 13 April, 2018, https://madisonarealymesupportgroup.com/2018/04/13/chronic-lyme-post-mortem-study-needed-to-end-the-lyme-wars/. Accessed 12 February, 2019.  

7.  Burrascano, Joseph.  “The History of Lyme Disease.”  ILADS.org, www.ilads.org/dr-burrascano-happy-holidays/?.  Accessed 21 February, 2019.

8.  Kocurek, J.  “How Lyme Got a Bad Rap – Lyme, Connecticut, That is.”  publichealthalert.org.  1 August 2006, https://www.publichealthalert.org/how-lyme-got-a-bad-rap—lyme-connecticut-that-is.html.  Accessed 12 February, 2019.

9. Ahern, Holly.  “Medical Stalemate:  What Causes Continuing Symptoms After Lyme Treatment?”   lymedisease.org.  19 February, 2019, https://www.lymedisease.org/lyme-stalemate-ahern/.  Accessed 25 February, 2019. 

10. Hughes, Claire.  “Report on Dangers of Antibiotic Use For Lyme Disease Sparks Controversy.”  www.timesunion.com June 20, 2017  https://www.timesunion.com/news/article/Report-on-dangers-of-antibiotic-treatments-for-11231166.php  Accessed 21 February, 2019.

11. Waisbren, Burton.  Treatment of Chronic Lyme Disease:  51 Case Reports and Essays in Their Regard.  (California:  BioMed Publishing Group, 2011).

12. Kraaijeveld, Huib.  “Interview With Professor Laane About the Suprression of Microscopy for Lyme Diagnostics.” https://on-lyme.org/en/, 9 December, 2017,  on-lyme.org/en/sufferers/lyme-stories/item/276-interview-with-professor-laane-about-the-suppression-of-microscopy-for-lyme-diagnostics  Accessed 21 February, 2019.

13. Milford Molecular Diagnostics.  “$57.1 Million Lyme Disease Lawsuit Filed Against CDC.”  Milford Molecular Diagnostics Press Release,  15 May, 2018.  http://www.dnalymetest.com/images/FINAL_-_Published_CDC_Lawsuit_News_Release_-_Nat_l_Version.pdf.  Accessed 21 February, 2019.